Literature DB >> 15308360

Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.

D J Pulford1, A Gates, S H Bridge, J H Robinson, D Ulaeto.   

Abstract

DNA vaccines might offer an alternative to the live smallpox vaccine in providing protective efficacy in an orthopoxvirus (OPV) lethal respiratory challenge model. BALB/c mice were immunised with DNA vaccines coding for 10 different single vaccinia virus (VACV) membrane proteins. After an intranasal challenge with the VACV IHD strain, three gene candidates B5R, A33R and A27L produced > or =66% survival. The B5R DNA vaccine consistently produced 100% protection and exhibited greatest efficacy after three 50 microg intramuscular doses in this model. Sero-conversion to these vaccines was often inconsistent, implying that antibody itself was not a correlate of protection. The B5R DNA vaccine induced a strong and consistent gamma interferon (IFNgamma) response in BALB/c mice given a single DNA vaccine dose. Strong IFNgamma responses were also measured in pTB5R immunised C57BL6 mice deficient for MHC class I molecules, suggesting that the memory response was mediated by a CD4+ T cell population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308360     DOI: 10.1016/j.vaccine.2004.02.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

1.  Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Authors:  Aklile Berhanu; Rebecca L Wilson; Dana L Kirkwood-Watts; David S King; Travis K Warren; Susan A Lund; Lindsay L Brown; Alex K Krupkin; Erin Vandermay; Will Weimers; Kady M Honeychurch; Douglas W Grosenbach; Kevin F Jones; Dennis E Hruby
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

Review 2.  The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins.

Authors:  Brian C DeHaven; Kushol Gupta; Stuart N Isaacs
Journal:  J Gen Virol       Date:  2011-06-29       Impact factor: 3.891

3.  Antibody responses to vaccinia membrane proteins after smallpox vaccination.

Authors:  Steven J Lawrence; Kathleen R Lottenbach; Frances K Newman; R Mark L Buller; Clifford J Bellone; John J Chen; Gary H Cohen; Roselyn J Eisenberg; Robert B Belshe; Samuel L Stanley; Sharon E Frey
Journal:  J Infect Dis       Date:  2007-06-04       Impact factor: 5.226

4.  Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.

Authors:  Minoru Kidokoro; Masato Tashiro; Hisatoshi Shida
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

5.  Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.

Authors:  Clement A Meseda; Anne E Mayer; Arunima Kumar; Alonzo D Garcia; Joseph Campbell; Paul Listrani; Jody Manischewitz; Lisa R King; Hana Golding; Michael Merchlinsky; Jerry P Weir
Journal:  Clin Vaccine Immunol       Date:  2009-07-15

6.  Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.

Authors:  Jay W Hooper; Anthony M Ferro; Joseph W Golden; Peter Silvera; Jeanne Dudek; Kim Alterson; Max Custer; Bryan Rivers; John Morris; Gary Owens; Jonathan F Smith; Kurt I Kamrud
Journal:  Vaccine       Date:  2009-10-13       Impact factor: 3.641

Review 7.  Smallpox vaccines for biodefense.

Authors:  Richard B Kennedy; Inna Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

8.  Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens.

Authors:  Pavlo Sakhatskyy; Shixia Wang; Chuanyou Zhang; Te-Hui Chou; Michael Kishko; Shan Lu
Journal:  Virology       Date:  2007-10-24       Impact factor: 3.616

9.  Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.

Authors:  Douglas W Grosenbach; Robert Jordan; David S King; Aklile Berhanu; Travis K Warren; Dana L Kirkwood-Watts; Shanthakumar Tyavanagimatt; Ying Tan; Rebecca L Wilson; Kevin F Jones; Dennis E Hruby
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 4.169

10.  Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax.

Authors:  Claire M Midgley; Mike M Putz; Jonathan N Weber; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2008-12       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.